Authors: | Enting, R. H.; Demopoulos, A.; Deangelis, L. M.; Abrey, L. E. |
Article Title: | Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide |
Abstract: | The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL. |
Keywords: | adult; cancer survival; clinical article; controlled study; treatment outcome; aged; disease-free survival; middle aged; survival analysis; retrospective studies; clinical trial; cancer recurrence; salvage therapy; cancer combination chemotherapy; drug efficacy; cancer radiotherapy; combined modality therapy; cytarabine; methotrexate; rituximab; temozolomide; brain neoplasms; dacarbazine; controlled clinical trial; cohort studies; neoplasm recurrence, local; anemia; leukopenia; thrombocytopenia; vincristine; drug resistance, neoplasm; procarbazine; central nervous system neoplasms; lymphoma, b-cell; cancer regression; antigens, cd20; antibodies, monoclonal; immunotherapy; antigens, neoplasm; antineoplastic agents, alkylating; remission induction; acute toxicity; brain lymphoma; drug evaluation; eye neoplasms; life tables; humans; human; male; female; priority journal; article |
Journal Title: | Neurology |
Volume: | 63 |
Issue: | 5 |
ISSN: | 0028-3878 |
Publisher: | Lippincott Williams & Wilkins |
Date Published: | 2004-09-14 |
Start Page: | 901 |
End Page: | 903 |
Language: | English |
PROVIDER: | scopus |
PUBMED: | 15365145 |
DOI/URL: | |
Notes: | Neurology -- Cited By (since 1996):119 -- Export Date: 16 June 2014 -- CODEN: NEURA C2 - 15365145 -- Source: Scopus |